The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women.
Bisphosphonates
Breast cancer
Osteoporosis
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
04
09
2018
revised:
16
10
2018
accepted:
22
10
2018
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Several observational studies have suggested a protective effect of oral bisphosphonates (BP) on the risk of breast cancer, but no such association has been seen in randomized control trials. The role of oral BP in breast cancer prevention remains unclear. To investigate the association between different levels of BP exposure and breast cancer incidence in a cohort of osteoporotic post-menopausal women. This historical prospective study was conducted using the computerized databases of Maccabi Healthcare Services (MHS) in Israel. Included in the study were osteopenic and osteoporotic women aged 55-75 years who started BP therapy between 1998 and 2012. The subjects were enrolled in MHS for at least 3 years before therapy initiation, and had a minimum follow-up of 5 years in MHS. Women with a previous cancer, and women treated with selective estrogen receptor modulators (SERMs) were excluded. BP exposure was expressed in quintiles of proportion of days covered (PDC) with BP during follow-up period and cancer incidence was ascertained by the Israel National Tumor Registry. Person-years of follow-up began on January 1st, 1998 and ended at the date of cancer diagnosis, death, or December 31st, 2012, whichever occurred first. A total of 11,717 patients (mean age = 66.87 ± 4.38) were eligible for the analysis. During a total of 130,252 person-years of follow-up, (mean 7.2 years) 173 incident cases of breast cancer were diagnosed. Compared to women with a PDC with BP of 20% or lower, the adjusted hazard ratio for breast cancer were HR = 0.81 (95%CI: 0.48-1.39), HR = 0.82 (95%CI: 0.50-1.33), HR = 0.72 (95%CI:0.45-1.15) and HR = 1.14 (95%CI:0.76-1.70) among women with 20-40%, 40-60%, 60%-80%, and 80% or higher, PDC, respectively. In this study, we did not find a significant association between oral BP therapy for osteoporosis and the risk of breast cancer in postmenopausal women. The discrepancy between our results and the reports of such an association in observational studies might originate from an indication bias.
Sections du résumé
BACKGROUND
BACKGROUND
Several observational studies have suggested a protective effect of oral bisphosphonates (BP) on the risk of breast cancer, but no such association has been seen in randomized control trials. The role of oral BP in breast cancer prevention remains unclear.
AIM
OBJECTIVE
To investigate the association between different levels of BP exposure and breast cancer incidence in a cohort of osteoporotic post-menopausal women.
SUBJECTS AND METHODS
METHODS
This historical prospective study was conducted using the computerized databases of Maccabi Healthcare Services (MHS) in Israel. Included in the study were osteopenic and osteoporotic women aged 55-75 years who started BP therapy between 1998 and 2012. The subjects were enrolled in MHS for at least 3 years before therapy initiation, and had a minimum follow-up of 5 years in MHS. Women with a previous cancer, and women treated with selective estrogen receptor modulators (SERMs) were excluded. BP exposure was expressed in quintiles of proportion of days covered (PDC) with BP during follow-up period and cancer incidence was ascertained by the Israel National Tumor Registry. Person-years of follow-up began on January 1st, 1998 and ended at the date of cancer diagnosis, death, or December 31st, 2012, whichever occurred first.
RESULTS
RESULTS
A total of 11,717 patients (mean age = 66.87 ± 4.38) were eligible for the analysis. During a total of 130,252 person-years of follow-up, (mean 7.2 years) 173 incident cases of breast cancer were diagnosed. Compared to women with a PDC with BP of 20% or lower, the adjusted hazard ratio for breast cancer were HR = 0.81 (95%CI: 0.48-1.39), HR = 0.82 (95%CI: 0.50-1.33), HR = 0.72 (95%CI:0.45-1.15) and HR = 1.14 (95%CI:0.76-1.70) among women with 20-40%, 40-60%, 60%-80%, and 80% or higher, PDC, respectively.
CONCLUSION
CONCLUSIONS
In this study, we did not find a significant association between oral BP therapy for osteoporosis and the risk of breast cancer in postmenopausal women. The discrepancy between our results and the reports of such an association in observational studies might originate from an indication bias.
Identifiants
pubmed: 31334001
doi: 10.1016/j.jbo.2018.10.001
pii: S2212-1374(18)30105-2
pii: 100202
pmc: PMC6616345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100202Références
J Bone Miner Res. 1999 Oct;14 Suppl 2:53-65
pubmed: 10510215
J Pharmacol Exp Ther. 2001 Feb;296(2):235-42
pubmed: 11160603
Eur J Epidemiol. 2003;18(12):1143-6
pubmed: 14758871
Endocr Relat Cancer. 2006 Mar;13(1):7-26
pubmed: 16601276
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34
pubmed: 16684881
Ann N Y Acad Sci. 2006 Apr;1068:367-401
pubmed: 16831938
Value Health. 2007 Jan-Feb;10(1):3-12
pubmed: 17261111
Harefuah. 2007 Jan;146(1):15-7, 79
pubmed: 17294841
N Engl J Med. 2007 May 3;356(18):1809-22
pubmed: 17476007
Cancer. 2008 Sep 1;113(5):907-15
pubmed: 18666209
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):831-47
pubmed: 19028359
Value Health. 2009 Sep;12(6):989-95
pubmed: 19402852
Adv Exp Med Biol. 2010;658:11-20
pubmed: 19950011
Br J Cancer. 2010 Mar 2;102(5):799-802
pubmed: 20160722
J Clin Oncol. 2010 Aug 1;28(22):3582-90
pubmed: 20567009
J Clin Oncol. 2010 Aug 1;28(22):3577-81
pubmed: 20567021
Bone. 2011 Jan;48(1):71-9
pubmed: 20655399
Int J Cardiol. 2011 Nov 3;152(3):345-9
pubmed: 20826019
Calcif Tissue Int. 2011 Apr;88(4):255-62
pubmed: 21253712
Int J Cancer. 2012 Sep 1;131(5):E717-25
pubmed: 22161552
JAMA Intern Med. 2014 Oct;174(10):1550-7
pubmed: 25111880
Lancet. 2015 Oct 3;386(10001):1353-1361
pubmed: 26211824
Medicine (Baltimore). 2015 Nov;94(46):e2014
pubmed: 26579808
J Bone Miner Res. 1994 Aug;9(8):1137-41
pubmed: 7976495
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2272-9
pubmed: 8637862
JAMA. 1996 Nov 6;276(17):1404-8
pubmed: 8892715
J Bone Miner Res. 1998 Apr;13(4):581-9
pubmed: 9556058
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874